EZH2 and cancer: In addition to activating mTORC1, SLC7A5 can also facilitate MYC and EZH2 signaling in cancer cells, while SLC3A2 has also been confirmed to facilitate uncontrolled proliferation of cancer cell through AKT, MAPK, and cell cycle-related P21/P27 signaling pathways (Zhao et al. 2022).